Vericel (VCEL) Competitors $37.11 +0.01 (+0.02%) Closing price 03:59 PM EasternExtended Trading$37.13 +0.02 (+0.06%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VCEL vs. VRNA, ROIV, ELAN, RVMD, LEGN, GRFS, TGTX, NUVL, LNTH, and AXSMShould you be buying Vericel stock or one of its competitors? The main competitors of Vericel include Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. Vericel vs. Its Competitors Verona Pharma PLC American Depositary Share Roivant Sciences Elanco Animal Health Revolution Medicines Legend Biotech Grifols TG Therapeutics Nuvalent Lantheus Axsome Therapeutics Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) and Vericel (NASDAQ:VCEL) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation. Which has more volatility and risk, VRNA or VCEL? Verona Pharma PLC American Depositary Share has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500. Comparatively, Vericel has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Is VRNA or VCEL more profitable? Vericel has a net margin of 1.25% compared to Verona Pharma PLC American Depositary Share's net margin of 0.00%. Vericel's return on equity of 1.09% beat Verona Pharma PLC American Depositary Share's return on equity.Company Net Margins Return on Equity Return on Assets Verona Pharma PLC American Depositary ShareN/A -69.65% -28.00% Vericel 1.25%1.09%0.73% Does the media favor VRNA or VCEL? In the previous week, Verona Pharma PLC American Depositary Share had 43 more articles in the media than Vericel. MarketBeat recorded 49 mentions for Verona Pharma PLC American Depositary Share and 6 mentions for Vericel. Vericel's average media sentiment score of 1.52 beat Verona Pharma PLC American Depositary Share's score of 0.49 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verona Pharma PLC American Depositary Share 19 Very Positive mention(s) 10 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vericel 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Very Positive Do institutionals and insiders have more ownership in VRNA or VCEL? 85.9% of Verona Pharma PLC American Depositary Share shares are owned by institutional investors. 4.8% of Verona Pharma PLC American Depositary Share shares are owned by insiders. Comparatively, 7.2% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better valuation & earnings, VRNA or VCEL? Vericel has higher revenue and earnings than Verona Pharma PLC American Depositary Share. Verona Pharma PLC American Depositary Share is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerona Pharma PLC American Depositary Share$118.54M71.65-$173.42M-$2.00-52.38Vericel$237.22M7.87$10.36M$0.031,236.90 Do analysts prefer VRNA or VCEL? Verona Pharma PLC American Depositary Share presently has a consensus price target of $109.00, suggesting a potential upside of 4.05%. Vericel has a consensus price target of $61.14, suggesting a potential upside of 64.77%. Given Vericel's stronger consensus rating and higher possible upside, analysts plainly believe Vericel is more favorable than Verona Pharma PLC American Depositary Share.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verona Pharma PLC American Depositary Share 0 Sell rating(s) 11 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.15Vericel 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryVericel beats Verona Pharma PLC American Depositary Share on 13 of the 16 factors compared between the two stocks. Get Vericel News Delivered to You Automatically Sign up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCEL vs. The Competition Export to ExcelMetricVericelMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.87B$2.93B$5.57B$9.32BDividend YieldN/A2.43%4.23%4.03%P/E Ratio1,237.3120.5028.6419.75Price / Sales7.87267.15432.34182.50Price / Cash127.4343.1536.0257.96Price / Book6.277.768.235.67Net Income$10.36M-$55.11M$3.24B$257.98M7 Day Performance-10.59%1.03%0.05%0.56%1 Month Performance-10.78%8.54%5.65%8.88%1 Year Performance-28.94%-2.26%26.57%14.24% Vericel Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCELVericel3.6942 of 5 stars$37.11+0.0%$61.14+64.8%-25.6%$1.87B$237.22M1,237.31300News CoveragePositive NewsVRNAVerona Pharma PLC American Depositary Share2.2694 of 5 stars$91.20-0.4%$107.36+17.7%+387.3%$7.76B$42.28M-45.6030Positive NewsAnalyst ForecastROIVRoivant Sciences2.7913 of 5 stars$10.74-2.3%$17.50+62.9%-1.2%$7.30B$29.05M-42.96860Positive NewsELANElanco Animal Health1.4909 of 5 stars$14.48-1.1%$15.33+5.9%+9.4%$7.19B$4.44B19.579,000RVMDRevolution Medicines4.5999 of 5 stars$36.67-3.2%$67.58+84.3%-17.8%$6.83B$11.58M-9.17250Analyst ForecastLEGNLegend Biotech3.37 of 5 stars$35.87+0.6%$72.60+102.4%-26.7%$6.59B$728.30M-60.802,609Gap UpGRFSGrifols3.5235 of 5 stars$8.87-2.3%$10.30+16.1%+19.7%$6.10B$7.81B7.5823,822News CoverageGap UpTGTXTG Therapeutics3.6141 of 5 stars$35.98-2.0%$40.80+13.4%+78.5%$5.71B$329M149.92290Positive NewsNUVLNuvalent3.3039 of 5 stars$77.93-3.2%$119.60+53.5%+1.8%$5.60BN/A-17.7540LNTHLantheus4.6203 of 5 stars$79.19-1.5%$130.50+64.8%-34.0%$5.48B$1.53B22.50700Positive NewsGap DownAXSMAxsome Therapeutics4.6945 of 5 stars$107.50+2.0%$172.33+60.3%+33.0%$5.29B$385.69M-18.63380Positive NewsAnalyst Revision Related Companies and Tools Related Companies VRNA Competitors ROIV Competitors ELAN Competitors RVMD Competitors LEGN Competitors GRFS Competitors TGTX Competitors NUVL Competitors LNTH Competitors AXSM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VCEL) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vericel Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Vericel With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VCEL Stock Alerts